Drug Profile


Alternative Names: Solosec; SYM 1219

Latest Information Update: 24 Mar 2017

Price : $50

At a glance

  • Originator Symbiomix Therapeutics
  • Class Antibacterials; Antiprotozoals; Nitroimidazoles; Small molecules
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Bacterial vaginosis

Most Recent Events

  • 23 Mar 2017 FDA assigns PDUFA action date of (17/09/2017) for secnidazole for Bacterial vaginosis (In adolescents, In adults)
  • 23 Mar 2017 The US FDA accepts NDA for secnidazole for Bacterial vaginosis (In adolescents, In adults) for review
  • 19 Jan 2017 Preregistration for Bacterial vaginosis (In adolescents, In adults) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top